In previous work, a single administration of anticarcinoembryonic antigen (anti-CEA) 131 I-labetuzumab radioimmunotherapy (RIT) after complete resection of colorectal liver metastases was well tolerated and significantly improved survival compared with controls. In the current phase 2 trial, the authors studied repeated RIT in the same setting, examining safety, feasibility, and efficacy. METHODS: Sixty-three patients (median age, 64.5 years) received RIT at 40 to 50 millicuries/m 2 per dose. Before the receipt of RIT, restaging was performed with computed tomography/magnetic resonance imaging and 18 F-fluorodeoxyglucose-positron emission to confirm that patients were "truly adjuvant." Patients who had elevated serum CEA levels or radiographically inconclusive new lesions were classified as "possibly nonadjuvant," but they also received RIT. Time to progression (TTP), overall survival (OS), and cause-specific survival (CSS) were calculated. The median follow-up was 54 months. RESULTS: After the first course of RIT, 14 of 63 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity; 19 patients did not receive the second course of RIT because of impaired performance status (N 5 5) or relapse (N 5 14). After the second course of RIT, 9 of 44 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity. Five patients developed myelodysplastic syndrome (MDS) from 22 to 55 months after their last RIT. The median TTP, OS, and CSS for all patients were 16, 55, and 60 months, respectively. The "truly adjuvant" patients (N 5 39) had an improved median TTP (not reached vs 6.1 months; hazard ratio, 0.12; P <.001), OS (75.6 vs 33.4 months; hazard ratio, 0.44; P 5.014), and CSS (not reached vs 41.4 months; hazard ratio,0.42; P 5.014) compared with "possibly nonadjuvant" patients (N 5 24). CONCLUSIONS: Repeated RIT with 131 I-labetuzumab is feasible but is associated with hematotoxicity. Survival is very encouraging, especially for "truly adjuvant" patients. However, the maximum safe dose of 
INTRODUCTION
Colorectal cancer (CRC) is 1 of the most prevalent malignancies in the United States and Europe. The liver is the predominant site of distant metastatic spread, and population-based data reveal colorectal liver metastasis (CLM) in approximately one-third of patients. 1 There is interdisciplinary consensus that complete (R0) resection is the only curative option. 2 However, approximately 70% of patients in whom R0 resection can be achieved develop metastatic recurrence within 3 years. In up to 40% of these patients, the liver remains the only site of metastasis. 3 This relapse is likely because of occult micrometastatic disease present at the time of CLM resection. Thus, perioperative and postoperative chemotherapy have been explored to improve the outcome of patients who undergo R0 resection of CLM. However, such trials failed to demonstrate a significant survival benefit. 4, 5 Recently, 3 European studies with triplet chemotherapy using either epidermal growth factor receptor or vascular endothelial growth factor antibodies in this setting were terminated because of insufficient recruitment (National Clinical Trials NCT01540435 and NCT01266187; clinicaltrials.gov) or presumed failure (National Clinical Trials NCT00394992; clinicaltrials.gov). Consequently, there is a continued need for innovative therapeutic strategies to improve patient outcomes, such as prolonging the time to progression (TTP) and increasing overall survival (OS). In a previous phase 1/2 study, we investigated single radioimmunotherapy (RIT) with 131 I-anticarcinoembryonic antigen (CEA) (CEA-related cell adhesion molecule 5 [CEACAM5]; cluster of differentiation 66e [CD66e]) antibody immunoglobulin G (IgG) labetuzumab in 23 patients after R0 resection of CLM and reported a doubled median OS during 5 years of follow-up compared with a contemporaneous cohort of patients who did not receive RIT. 6, 7 The objective of the current study was to confirm and extend these earlier findings by determining the safety, feasibility, and long-term therapeutic effects of repeated RIT in a larger group of consecutive patients with CLM.
MATERIALS AND METHODS

Patient Characteristics
Between May 2005 and July 2009, patients were enrolled into this phase 2 single-center study after signing informed consent for the protocol approved by the Institutional Ethics Committee. The primary endpoint of the study was safety in terms of the number and percentage of patients experiencing grade 4 toxicity according to National Cancer Institute Common Toxicity Criteria (NCI-CTC) (version 2.0; National Cancer Institute, Bethesda, Md; available at: http://ctep.cancer.gov/reporting/ctc. html, Accessed on May 15, 2016) . Secondary endpoints were related to efficacy, including TTP, OS, and causespecific survival (CSS). Sample size estimates were based on our previous study of RIT, in which 3 of 23 patients (13%) had grade 4 toxicity. 6 We considered a maximum rate of 25% grade 4 toxicity as limiting. Assuming that the rate of grade 4 toxicity would not be much higher in our current trial, we estimated that, with a sample size of 60 patients, we would demonstrate a toxicity rate <25% with 95% confidence. The entry criteria included age 18 years, a diagnosis of resected primary CRC, histopathologically confirmed R0 resection of all CLMs (in patients with synchronous CLM, simultaneous resection of both primary CRC and CLM was allowed), immunohistochemical confirmation of high CEA expression in CLM, a minimal life expectancy >3 months, a Karnofsky performance index >70%, and normal serum chemistries and complete blood cell count (CBC). To estimate the risk for early metastatic recurrence, patients were classified according to the clinical score published by Fong et al. 8 In addition, the TNM staging system for metastatic CRC, as proposed by Gayowski et al, 9 was applied to all specimens.
Before RIT, a 4-week to 6-week interval was required after surgery. Normalization of bone marrow function, as measured by CBC, was required after any previous therapy. Prior systemic chemotherapy was permitted, but no patient was allowed to receive any chemotherapy or antibody-based therapy after CLM resection until there was evidence of relapse. Euthyroid patients were blocked with perchlorate or potassium iodide.
Two weeks before the first cycle of RIT, all patients were subjected to intensified restaging, including serum CEA level; contrast-enhanced, multislice computed tomography (CT) and/or magnetic resonance imaging (MRI); as well as 18 F-fluorodeoxyglucose (FDG) wholebody positron-emission tomography (PET). In some of the first 15 patients, we observed not only persistently elevated serum CEA levels early after surgery without radiographic evidence of recurrent disease but also inconclusive lesions on imaging studies. An inconclusive lesion was defined as a newly appearing lesion without malignant character on CT and/or newly appearing lesions on PET without a pathomorphologic confirmation by CT. Because all patients underwent intraoperative ultrasound at the time of liver surgery, and all known lesions were resected, we concluded that withholding RIT in these patients would not be justified based on such weak evidence of recurrence. However, if no new suspicious lesion was observed by PET or CT, and if serum CEA levels were normal (<5 ng/mL), then patients were classified as "truly adjuvant." If there were inconclusive lesions on any scan or persistently elevated serum CEA titers, then patients were censored as "possibly nonadjuvant." The staging procedures were repeated before the second RIT cycle.
Antibody, Radiolabeling, Administration, and Dosimetry
The humanized anti-CEACAM5 monoclonal antibody hMN-14 (labetuzumab; Immunomedics, Inc, Morris Plains, NJ) was labeled with 131 I, as previously described. 7, 10 Thirty minutes before receipt of intravenous RIT, patients received 4 mg ondansetron, 2 mg clemastine, 100 mg prednisolone, and 200 mg cimetidine. I-labetuzumab was given intravenously as previously described, 7 with vital signs obtained from 10 minutes pretherapy until 240 minutes after the infusion was started. Whole-body c-camera imaging was performed according to an established protocol. 7 To confirm the previous results published by Hajjar et al, 11 dosimetry and pharmacokinetics using 5 millicuries (mCi)/m 2 131 Ilabetuzumab were performed in 4 patients before the first RIT. Whole-body clearance was determined by serial whole-body scans, beginning immediately after the end of the infusion before voiding, after 4 and 6 hours, and daily during the next 7 days. For dosimetry, regions of interests were drawn over the whole body and selected organs (liver, spleen, kidneys, heart, lungs) to determine geometric mean counts. The residence times were calculated, and the radiation-absorbed doses to the organs and the whole body were derived using MIRDOSE-3 software. 12 Bone marrow dosimetry was calculated by repetitive blood sampling over 8 days, and blood activity was measured with a c-counter using by the method reported by Shen et al. 13 After RIT and until the patients were discharged, CBCs and serum biochemistry tests were performed daily. Also, blood samples were taken weekly for 3 months to monitor hematologic, renal, and hepatic toxicities. If restaging before the second cycle of RIT identified a resectable metastatic relapse, then patients were scheduled for re-resection before the second cycle of RIT. Otherwise, patients were planned for chemotherapy at the investigator's discretion. Follow-up procedures, including serum CEA, abdominal ultrasound, CT/MRI, and FDG-PET, were performed every 3 months after the last cycle of RIT, according to the study protocol, conforming to the guidelines of the German Cancer Society.
14 All adverse events were documented according to NCI-CTC version 2.0.
Dosing
On the basis of previous experience of single RIT, the dose was based on each patient's body surface area (mCi/ m 2 ). 6, 7 All patients in the current study were intended to receive 2 doses of 50 mCi/m 2 131 I-labetuzumab 3 months apart (individually applied doses are listed in Supporting Table 1 ; see online supporting information). The protocol allowed dose de-escalation if the history of the patient was suggestive of a poor bone marrow reserve (eg, prolonged hematologic toxicity [NCI-CTC grade > 3] after the first RIT).
Statistical Analysis
Differences between the 2 subgroups of patients were calculated using the Mann-Whitney U test (age, number of chemotherapy periods, and chemotherapy regimen) and the chi-square test (for all other variables). Survival was calculated from the time of liver resection to an event or last follow-up. The Kaplan-Meier method was used to calculate TTP, OS, and CSS, and significance was computed using a Cox proportional-hazards model. Median survival (ie, the time at which the estimated proportion of survivors drops below 50%) was calculated with a confidence interval (CI) of 95%. Proportions that did not drop below 50% or could not be estimated were designated as not reached (NR). Survival analysis was performed independent of the number of RIT cycles received. For TTP analyses, patients who were alive and free of recurrence or who died without having a recurrence were censored. Furthermore, recurrence after the first cycle of RIT was counted as an event for TTP analysis even when patients proceeded to the second RIT cycle after re-resection. For CSS analyses, events were deaths in the setting of recurrent CRC or in which a correlation to treatment toxicity (long-term toxicity; eg, MDS) was most likely. For all analyses, P values < .05 were considered statistically significant. Calculations were performed using the R software packages Stats and Survival (version 2.12.2; R Project for Statistical Computing, Vienna, Austria; available at: www.r-project.org, Accessed on March 1, 2011).
RESULTS
Patient Characteristics
Patient characteristics and previous treatment data for all 63 patients are summarized in Table 1 . Patients received RIT after resection of first and recurrent CLM in 53 and 10 patients, respectively. To achieve R0 resection, major liver surgery (ie, 2-stage resection with portal vein ligation) was necessary in 12 patients (19%). Figure 1 is a flow chart of the current trial. The median time between liver surgery and the first cycle of RIT was 8 weeks (range, 2-23 weeks). Twenty-four patients were assigned to the "possibly nonadjuvant" subgroup because of postoperatively persistent CEA elevation above the reference level (N 5 9), new inconclusive lesions on imaging studies (N 5 11), or both criteria (N 5 4), respectively. Specifically, 38 patients did not have any sign of recurrent disease at restaging, before the second cycle of RIT. In 6 patients (1 in the "truly adjuvant" subgroup and 5 in the "possibly nonadjuvant" subgroup), limited metastatic recurrence did develop; however, after complete re-resection, these patients received the second cycle of RIT.
Original Article Only 1 cycle of RIT was received by 19 patients because of impaired performance status (N 5 5) or evidence of more extensive metastatic relapse (N 5 14) before the second cycle of RIT (detailed treatment data are provided in Supporting Table 1 ; see online supporting information). Of those 19 patients, 12 were in the "possibly nonadjuvant" subgroup.
Acute Toxicity
No infusion-related adverse events were observed. Calculated median organ doses in the 4 patients who had dosimetric data on the activity of 50 mCi/m 2 body surface 131 I-labetuzumab were 6.3 grays (Gy) (1.76 milligrays/ megabecquerels [mGy/MBq]) for kidneys, 4.8 Gy (1.33 mGy/MBq) for lungs, 13.7 Gy (3.94 mGy/MBq) for heart, 7.1 Gy (1.97 mGy/MBq) for spleen, and 2.9 Gy (0.83 mGy/MBq) for liver. The median bone marrow dose in these 4 patients was calculated as 3.3 Gy (range, 1.8-4.5 Gy). The short-term (within 12 weeks after RIT) and long-term World Health Organization grade 3 and 4 toxicities were only hematologic. After the first cycle of RIT, a median nadir of 6 weeks (range, 3-8 weeks) and 5 weeks (range, 3-6 weeks) was observed for leukocytes and platelets, respectively. After the second cycle of RIT, the median nadir for leukocytes and platelets was 6 weeks (range, 4-10 weeks) and 6 weeks (range, 3-8 weeks), respectively ( Fig. 2A-F) . Toxicity grades in relation to single versus repeated RIT are provided in Supporting Table 2 (see online supporting information). Overall, patients who received 2 cycles of RIT experienced more toxicity than who received a single cycle; however, the difference was statistically significant only for hemoglobin. Eight to 12 weeks after RIT, peripheral blood counts recovered to former levels (13 patients had received granulocytecolony-stimulating factor at the investigator's discretion, and 16 patients had received platelet transfusions).
Late Toxicity
Five patients were diagnosed with MDS 22 to 55 months after their last RIT (Table 2 ). According to the International Prognostic Scoring System (IPSS/IPSS-R), [15] [16] [17] they were classified with high-risk, secondary MDS. Four of these 5 patients died from blast crisis, sepsis after hip surgery, fungal pneumonia during acute myeloid leukemia-like chemotherapy, or multiorgan dysfunction 0, 3, 3, and 10 months after their diagnosis of MDS, respectively. One patient with MDS who also was diagnosed with intermediate 2-risk refractory cytopenia with multilineage dysplasia was still alive 79 months after the last cycle RIT and was receiving best supportive care without any specific MDS treatment. Four of 5 patients had normal peripheral blood counts before each cycle if RIT. Only 1 patient presented with mild bicytopenia before the first cycle of RIT and had mild pancytopenia before the second cycle of RIT (Table 2, patient 5).
Cancer Relapse
In 40 of 63 patients (63%), recurrent cancer was diagnosed during a median follow-up of 54 months (range, 6-106 months). The principal single sites of recurrence were liver (N 5 18; 29%) and lungs (N 5 11; 17%). In the "truly adjuvant" group, cancer recurrence was detected in 18 of 39 patients (46%); and, in the "possibly nonadjuvant" group, cancer recurred in 22 of 24 patients Figure 1 . This is a flow chart of the current trial. CEA indicates carcinoembryonic antigen; CLM, colorectal liver metastases; CT, computed tomography; FDG-PET, 18 F-fluorodeoxyglucose-positron emission tomography; MRI, magnetic resonance imaging; RIT, radioimmunotherapy.
(92%). At the end of follow-up, 28 of 63 patients (44%) had died of tumor progression.
Efficacy
The median TTP, OS, and CSS for all 63 patients were 16 months (95% CI, 8.6-60.3 months), 55 months (95% CI, 41.1 months to NR) and 60.3 months (95% CI, 42.1 months to NR), respectively. TTP and OS data from the current trial were compared with those from the updated survival analysis of our initial trial with single RIT (data not shown in detail) and indicated no significant differences (but there was a trend in favor of repeated RIT) between the 2 trials (Fig. 3) . Furthermore, a subgroup analysis was performed comparing the "truly adjuvant" patients (N 5 39) with the "possibly nonadjuvant" patients (N 5 24) (Fig. 4A-C) . The "truly adjuvant" patients had significantly improved median TTP (NR vs 6.1 months; hazard [HR], 0.12; 95% CI, 0.06-0.25; P < .001), OS (75.6 vs 33.4 months; HR, 0.44; 95% CI, 0.23-0.85; P 5 .014), and CSS (NR vs 41.4 months; HR, 0.42; 95% CI, 0.21-0.84; P 5 .014) compared with the "possibly nonadjuvant" patients.
DISCUSSION
The outcome of patients after R0 resection of CLM is a clinical dilemma. Currently, the rate of recurrence is as high as 70% within 3 years, 3 as mentioned above, which is most probably because of occult micrometastatic disease. Along with the limited value of conventional postoperative chemotherapy in terms of survival, 4, 5 side effects, such as vomiting, neurotoxicity, and hepatotoxicity, may reduce patients' compliance to adjuvant treatment. In particular, patients with primarily borderline resectable or even recurrent CLM already may be seriously affected by the toxicity of previously received intensified chemotherapies and, thus, are likely to refuse chemotherapy in the postoperative setting.
Given the high prevalence of CEA expression by CRC cells, 18 anti-CEA RIT could serve as an innovative adjuvant treatment option. Indeed, RIT with radiolabeled antibodies has been introduced as therapy for lymphomas 19 but has experienced poorer results when used as monotherapy in patients with advanced solid tumors. 20 However, the promising efficacy results of single RIT after R0 resection of CLM 6,7 encouraged us to investigate the safety and long-term therapeutic (7) (q22) [3] /46,XX [1] 45, XY, 27 [6] / 46,XY [14] 46,XY,del (5) effects of repeated RIT in a larger group of consecutive patients.
The acute toxicity observed in the current study was limited to hematologic toxicity, consistent with earlier observations for single RIT. 6, 7 The dosimetry data revealed a bone marrow dose up to 4.5 Gy when patients received 50 mCi/m 2 of 131 I-labetuzumab, comparable to the data reported by Hajjar et al using the same antibody in patients with unresectable, metastatic CRC. 11 However, as expected, we observed higher hematologic toxicity in patients who had cumulative radioactivity. Therefore, the cumulative fractionated activity of 131 I-labetuzumab doses from < 70 to 80 mCi/m 2 seems to be more reasonable in further investigations with RIT, similar to other studies. 21, 22 In 2 patients, treatment with thionamides for hyperthyroidism may have contributed to the grade 4 white blood cell toxicity reported after the first cycle of RIT, because agranulocytosis is a well known side effect of thionamides. 23 After discontinuing thionamides, 1 of these patients received a second cycle of RIT and developed no signs of cumulative hematologic toxicity. The second patient was not retreated because of recurrent disease diagnosed at restaging before the second cycle of RIT.
The long-term follow-up of our study cohort enabled us to identify MDS as the only clinically relevant, late, cumulative toxicity ( Table 2 ). Only 1 patient had mild cytopenia before RIT that did not require any diagnostics or specific treatment. Retrospectively, we cannot exclude the possibility that this patient suffered from an unrecognized, early stage of MDS before RIT. The remaining 4 patients with secondary MDS did not have any abnormal CBCs before RIT that could have indicated underlying hematologic disease. The observed short latency of 2 to 4 years between RIT and MDS argues for a cumulative toxic effect in long-term, multimodality-treated patients. In our previous trial, patients received doses of 55 to 60 mCi. Five of those patients had received neoadjuvant or adjuvant radiotherapy (RT). Even after a median long-term follow-up 91 months, we did not observe any MDS in this cohort. 7 In the current trial, 8 patients had received RT before RIT. One patient who later developed MDS had received short-term RT (5 3 5 Gy) instead of long-term RT. However, that patient underwent primary tumor surgery after RT in September 2003 but received RIT in February 2007. Data from a large phase 3 trial indicated no difference in late toxicity between short-term and long-term RT in patients with rectal cancer. 24 Although we assume that the development of MDS is caused in part to the intensive pretreatment of our patients, we did not observe a correlation between previous RT or the time from previous RT to RIT and MDS development. Consequently, long-term follow-up with repeated CBCs is recommended to detect such late hematologic toxicity. Although the incidence of secondary MDS in our patients (8%) was not higher than the 10% incidence of MDS after RIT with 131 I-tositumomab reported in patients with relapsed non-Hodgkin lymphoma, 25 and although the results were consistent with the general finding that extensive previous chemotherapy or RT may induce secondary MDS or acute leukemia in up to 10% of patients within 10 years after treatment, 26, 27 the findings provoke concern, because we used RIT in an adjuvant setting after patients underwent complete resection of all CLM.
The clinical potential of an innovative oncologic treatment like RIT with 131 I-labetuzumab depends not only on its safety but, more significantly, on its benefit in terms of improved survival. Indeed, this and our previous study 6, 7 are among rare reports 22 defining a survival advantage for RIT in solid cancers. However, we did not observe a significant survival improvement compared with our initial trial. This may be related in part to the more advanced disease in our current cohort and to the finding that 30% of patients did not proceed to the second cycle of RIT.
It is well known that, in patients with solid cancers, RIT is most effective for treating microscopic disease. 28 On the basis of the larger sample size in the current trial, the intensified restaging before the first cycle of RIT allowed us to discriminate between the "truly adjuvant" and "possibly nonadjuvant" patients, which was not possible in our first RIT trial. Indeed, it was recently demonstrated that a persistently elevated CEA titer after CLM resection is an independent predictor of poor progressionfree survival. 29 The subgroup analysis revealed significantly higher median TTP, OS, and CSS for "truly adjuvant" patients compared with "possibly nonadjuvant" patients. Table 3 provides a comparison of our survival results with those published for both a standard of care advocating a "wait-and-see" course and perioperative or adjuvant chemotherapy. It is noteworthy that there are differences in eligibility criteria between those studies and our current trial.
Kim et al excluded patients who had received any neoadjuvant chemotherapy before undergoing liver resection. 30 In addition, those authors did not report on multistage resections, including portal vein ligation and patients with recurrent metastases. In the European Organization for Research and Treatment of Cancer 40983 trial, patients who had received previous oxaliplatin-based chemotherapy were excluded 4 along with those who had >4 CLM. Finally, Ychou et al excluded patients who had previously received irinotecan-based adjuvant chemotherapy, liver resection/ablation, and chemotherapy before undergoing liver resection; and eligibility for multiplestep resections, including portal vein ligation, was not reported. 5 This is important, because it has been demonstrated that portal vein embolization or ligation induces tumor growth and thereby has the potential to alter progression-free survival. [31] [32] [33] Although none of those trials included such subgroup analyses, the survival data from the "truly adjuvant" patients are so encouraging that, although this was a nonrandomized phase 2 trial, we believe there is a treatment-related survival improvement even in the presence of any selection bias.
Since the onset of our study, other improvements of anti-CEA immunoconjugate therapy have been made, which may also be of interest in the adjuvant setting described in this report. One of these is pretargeted RIT using bispecific antibodies. Separating the targeting Original Article antibody from its subsequent therapeutic agent allows the antibody to localize to its target and clear from the blood before the administration of a radioactive agent to which the bispecific antibody also binds. 34 A different approach is conjugating the antibody not to a radionuclide but to a cytotoxic agent (antibody-drug conjugate [ADC]). In this regard, SN-38, the active form of the antitopoisomerase-1 drug irinotecan, has been investigated in a human colonic tumor model. Those experiments revealed significant tumor growth control and increased median survival for animals that received the labetuzumab-SN-38 ADC at nontoxic doses, which were a fraction of the irinotecan doses used in controls. 35 Very recently, early data from a phase 1/2 trial investigating labetuzumab-SN-38 in heavily pretreated patients with metastatic CRC have been presented. 36 In that trial, the only relevant toxicity was neutropenia, which was manageable, but without the usual severe diarrhea known for irinotecan therapy. Hence, either or both of these alternate approaches may improve on the results reported here and could also reduce the risk of MDS by mitigating or avoiding nontargeted radiation.
Compared with radiolabeled antibodies, which would not be used earlier than 10 to 14 days after resection, when surgical complications and reoperation are unlikely, an ADC may permit intraoperative and/or early postoperative administration. This aspect is of major importance, because liver surgery promotes the release of numerous cytokines and growth factors that contribute to the proliferation of occult, residual, intrahepatic tumor cells. 37 This is most likely a major reason for the poor results from conventional chemotherapy usually given not earlier than 4 to 6 weeks after extended CLM surgery.
In conclusion, repeated RIT with 131 I-labetuzumab is feasible. However, compared with our previous single RIT study, the repeated RIT doses were associated with higher than anticipated acute hematotoxicity and secondary MDS development, the latter providing concern in the adjuvant setting. Nevertheless, the TTP and OS results produced with this fractionated, repeated RIT are very encouraging and provide a proof of concept for the effectiveness of anti-CEA RIT in the setting of occult, micrometastatic disease after R0 resection of CLM. Given the mentioned toxicities and the finding that repeated RIT exhibited a trend (but no significant difference compared with single RIT) toward further improvement in survival, we conclude that the maximum safe dose of This was the group of "truly adjuvant" patients.
targeting CEA with nonradionuclide therapeutic agents should be evaluated.
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